| Objective : To investigate the clincal value of DCs sensitized by renal cell carcinoma antigen associated with CIK used in human renal cell carcinoma after surgery.Methods: Controlled 269 cases of renal cell carcinoma patients from April 2009 to April 2014 in our hospital. Divided all patients into two groups after radical nephrectomy or nephron sparing surgery : 129 cases were treated by DCs-CIK,another 140 cases treated by IFN-α. Take DCs-CIK group patients treated tumor tissue and peripheral blood, culture and Amplificate DCs which sensitized by renal cell carcinoma associated antigen and CIK in vitro.Then returned it to the patient after Sterility test and flow cytometry phenotype. The control group were treated with IFN-α subcutaneous treatment. Summarize clinical basic information,and observed adverse reactions during treatment. Compared the two groups of patients with 3-year, 5-year overall survival and progression-free survival. Univariated and multivariated analysis age, sex, tumor location, surgical approach, histological grade, tumor stage, lymph node metastasis, distant metastasis, immune therapeutic relationship and progression-free survival.Results:There is no significant difference between gender, age, tumor location,surgical, pathological grade(P>0.05). Bacterial, fungal or endotoxin contamination was not detected before reinfusion. Flow cytometry showed that the expression of CD83 is about 53.9%,and CD86 is about 74.1%, in line with the expression levels of mature DCs; the expression of CD3 is about 74.7%,and CD16+56 is about26.8%, in line with the expression levels of mature CIK. DCs-CIK group of 3-year and 5-year progression-free survival rates was significantly higher than IFN-α. The research also found that, for the early and mid-kidney carcinoma patients, the clinical efficacy of DCs-CIK therapy was superior to IFN-α treatment; but for patients with advanced kidney carcinoma and found no DCs-CIK therapy is superior to IFN-α treatment.Univariate analysis showed that tumor stage, lymph node metastasis, distant metastasis, immune therapy were the prognostic factors of renal cell carcinoma; Multivariate analysis showed that tumor stage and immunotherapy were provided with Clinical Significance. In addition, the DCs-CIK group found no serious adverse events, and occasionally a transient fever after infusion, but self-healing within a few hours after the infusion, and the overall rate of adverse events was significantly lower than the control group.Conclusion:DCs-CIK can significantly prolong progression-free survival, reduce overall mortality for early and mid-renal cell carcinoma;and for advanced cell carcinoma it also has the same clinical efficacy with IFN-α, but its adverse reactions was lower than IFN-α.So it’s worth in clinical practice. |
PDF Full Text Request